Skip to main content

Advertisement

Table 1 Patient demographics and pathologic features

From: Clinical outcomes and prognostic factors for gastric cancer patients with bone metastasis

Factors   Patient (n = 34)
Age (years) Median (range) 66 (39–78)
Gender Male 26 (76.5%)
Female 8 (23.5%)
ECOG performance status 0–1 16 (47.1%)
2–4 18 (52.9%)
Bone pain Present 11 (32.4%)
Absent 23 (67.6%)
Location Upper 1/3 5 (14.7%)
Middle 1/3 17 (50.0%)
Lower 1/3 5 (14.7%)
Whole stomach 7 (20.6%)
Histologic type Differentiated 15 (44.1%)
Undifferentiated 19 (55.9%)
Stagea I 1 (2.9%)
II 3 (8.8%)
III 8 (23.5%)
IV 22 (64.7%)
Treatment for primary tumor Surgery 16 (47.1%)
Chemotherapy 18 (52.9%)
ALP (IU/L) Median (range) 375.5 (157–2743)
LDH (IU/L) Median (range) 249 (117–1481)
CEA Median (range) 8.6 (1.0–3508)
CA19-9 Median (range) 53.7 (0.6–1814.0)
CA125 Median (range) 20.3 (7.9–1099)
Diagnostic modality CT 30 (88.2%)
Bone scan 10 (29.4%)
MRI 9 (26.5%)
PET-CT 1 (2.9%)
Pattern of bone metastasis Synchronous 10 (29.4%)
Metachronous 24 (70.6%)
Number of bone metastases Single 12 (35.3%)
Multiple 22 (64.7%)
Extraosseous metastasis Present 26 (76.5%)
Absent 8 (23.5%)
Treatment of bone metastasis Chemotherapy 26 (76.5%)
Radiotherapy 5 (14.7%)
Best supportive care 4 (11.8%)
  1. Abbreviations: ALP serum alkaline phosphatase, LDH lactate dehydrogenase, CEA serum carcinoembryonic antigen, CA carbohydrate antigen, CT computed tomography, MRI magnetic resonance imaging, PET positron emission tomography
  2. aStage was according to the 14th edition of the Japanese classification of gastric carcinoma